MassDevice Podcast: Soteira CEO Larry Jasinski
February 7, 2012 by Arezu Sarvestani
Soteira CEO Larry Jasinski talks to MassDevice about overcoming the odds with spinal fusion devices and managing a 510(k) win even after the FDA switched things up mid-stream.
Click to play
Soteira CEO Larry Jasinski is no stranger to adversity.
In the last 5 years the spinal fusion device maker has overcome criticism from the research community and mid-application surprises from the FDA, but its newest 510(k) win is a testament to its persistence.
The Natick, Mass.-based vertebroplasty firm emerged from stealth mode once again at the end of last year to announce that it finally landed clearance for its Shield kyphoplasty system and is preparing for market launch
Sign up to get our free newsletters delivered straight to your inbox
Similar entries
Being low-key is part of the company's character, Jasinski told MassDevice, but so is tenacity.
When the FDA suddenly shifted its expectations of the Shield application, after having agreed to a pathway to clearance with Soteira, Jasinski didn't fight the reviewers – he went over their heads.
Permalink
FDA Database Search
RECENT BLOG POSTS
- Funding R&D: High prices, overuse a failed strategy
- FDA's role in promoting women's health
- New partnership to boost use of GMDN codes for medical devices
- FDA's modern "Corps of Discovery" in China
- Consumers lose in latest FDA user fee bill; COI restraints disappear
- Gamification
- Cool technology of the week
- A new day: Interim thoughts on the 2012 Heart Rhythm Society scientific sessions
- When a child loses milestones, consider sleep EEG studies
- Red or blue pill for payment reform? Both won't work
Features
